Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report report published on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Down 10.2 %

NASDAQ BCLI opened at $2.37 on Tuesday. Brainstorm Cell Therapeutics has a twelve month low of $2.01 and a twelve month high of $11.89. The stock has a 50-day moving average of $0.40 and a 200 day moving average of $0.45. The stock has a market capitalization of $166.09 million, a price-to-earnings ratio of -7.44 and a beta of 0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same period in the previous year, the business posted ($0.27) EPS. Equities analysts predict that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.